Connect
MJA
MJA

Potential impact of AUSFTA on Australia's blood supply

Wolfgang Frenzel
Med J Aust 2007; 186 (8): . || doi: 10.5694/j.1326-5377.2007.tb00983.x
Published online: 16 April 2007

In reply: I would like to respond to the letter by Kennedy et al regarding the passive transfer of human T-lymphotropic virus (HTLV) antibodies following Octagam (intravenous immunoglobulin [IVIg]) administration.


  • Octapharma, Vienna, Austria



Competing interests:

Octapharma is the manufacturer of Octagam. I am employed by Octapharma in the role of International Medical Director.

  • 1. Australian Government Department of Health and Ageing. Therapeutic Goods Administration. Standards for blood components. Therapeutic Goods Order No. 74. 2006. http://www.tga.gov.au/docs/html/tgo/tgo74.htm (accessed Mar 2007).
  • 2. Council of Europe. Guide to the preparation, use and quality assurance of blood components. 11th ed. January 2005. Strasbourg: Council of Europe Publishing, 2005.
  • 3. US Food and Drug Administration. Code of Federal Regulations, Title 21, Part 610, Subpart E. Testing requirements for communicable disease agents (4-1-04 edition). Rockville, Md: FDA, 2004.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.